Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.